Egfr inhibitörleri ile tedavi edilen metastatik kolon kanserli hastalarda hastalıksız sağkalımı etkileyen faktörler
Küçük Resim Yok
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
İnönü Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Giriş ve amaç: Kolorektal kanserler gastrointestinal sistemin en sık görülen kanserleridir. Evre 4 kolorektal kanser tanısı almış hastaların tedavisinde EGFR inhibitörleri önem arz etmektedir. Biz de çalışmamızda EGFR ile tedavi edilen metastatik kolon kanserli hastalarda hastalıksız sağkalımı etkileyen faktörleri araştırmayı amaçladık. Gereç ve yöntemler: Çalışmaya İnönü Üniversitesi Tıp Fakültesi Turgut Özal Tıp Merkezi'nde Ocak 2002- Aralık 2021 tarihleri arasında Medikal Onkoloji bölümünde takip ve tedavi alan, 18 yaşından büyük hastalar dahil edildi. Retrospektif veriler değerlendirildi. Hasta verileri hasta dosyaları ve ENLİL bilgisayar otomasyon sisteminden elde edildi. Bulgular: Çalışmaya alınan 101 hastadan 69'u erkek, 32'si kadın idi. Bunlardan 55 yaş üstü hasta sayısı 74 iken, 55 yaş altı hasta sayı 27 idi. 101 Hastanın 81'inde sol tutulum, 20'sinde sağ tutulum görüldü. 101 hastanın 55'ine rektum kanseri, 46'sına da kolon kanseri tanısı konulmuştu. Hastaların 59'u Setuximab, 42'si panitumumab tedavisi almıştı. 101 hastanın 47'sinde metastaz karaciğerde görülürken, 54'ünde karaciğer dışında görülmüştü. 101 hastanın 50'si 1.basamak tedavisi alırken, 51 hasta ise diğer basamak tedavileri görmüştü. Yaş, cinsiyet, ilaç farkı, primer tümör lokalizasyonu (tanı), tutulum yeri ile hastalıksız sağkalım arasında istatistiksel olarak anlamlı ilişki olmadığı tespit edilirken (p>0.05); karaciğer metastazları olan, diğer basamak tedavi alan hastalarla hastalıksız sağkalım arasında anlamlı ilişki olduğu görüldü (p<0.05). Sonuç: EGFR inhibitörleri ile tedavi edilen metastatik kolon kanser tanılı hastalarda karaciğer metastazı olan hastalar ve 1. basamak dışı tedavi alanlar ile hastalıksız sağkalım arasında anlamlı ilişki görüldü. Anahtar sözcükler: Metastatik kolon kanseri, EGFR, hastalıksız sağkalım, yaş, cinsiyet, ilaç, tanı, tutulum, karaciğer, basamak tedavi.
Introduction and purpose: Colorectal cansers are the most common cansers of the gastrointestinal tract. EGFR inhibitors are important in the treatment of patients diagnosed with stage 4 colorectal canser. İn our study, we aimed to investigate the factors affecting disease-free survival in patients with metastatic colon canser treated with EGFR inhibitors. Materials and methods: Patients older than 18 years of age who received treatment and follow-up in the Department of Medical Oncology at Turgut Özal Medical Center between January 2002 and December 2021 were included in the study. Retrospective data were evaluated. Patient data were obtained from patient files and ENLİL computer automation system. Results: Of the 101 patients included in the study, 69 were male and 32 were female. While the number of patients over 55 years of age was 74, the number of patients under 55 was 27. Left ivolvement was ovserved in 81 of 101 patients and right involvement was seen in 20 patients. Of 101 patients, 55 were diagnosed with rectal cancer and 46 with colon cancer. Of the patients, 59 received cetuximab and 42 received panitumumab. While metastases were identified in the liver in 47 of 101 patients; 54 of the patients had metastases outside the liver. Fifty of 101 patients received first-line treatment, while 51 patients received other-line treatments. There was no statistically significant relationship between age, gender, drug difference, primary tumor localization (diagnosis), site of involvement and disease-free survival (p>0.05); there was a significant correlation between disease-free survival and patients with liver metastases who received other step therapy (p<0.005). Conclusion: İn patients with metastatic colon cancer treated with EGFR inhibitors, a significant correlation was found between patients with liver metastases and those who received non-first-line treatment and disease-free survival. Key words: Metastatic colon canser, EGFR inhibitors, disease-free survival, age, gender, drug, diagnosis, involvement, liver, step therapy.
Introduction and purpose: Colorectal cansers are the most common cansers of the gastrointestinal tract. EGFR inhibitors are important in the treatment of patients diagnosed with stage 4 colorectal canser. İn our study, we aimed to investigate the factors affecting disease-free survival in patients with metastatic colon canser treated with EGFR inhibitors. Materials and methods: Patients older than 18 years of age who received treatment and follow-up in the Department of Medical Oncology at Turgut Özal Medical Center between January 2002 and December 2021 were included in the study. Retrospective data were evaluated. Patient data were obtained from patient files and ENLİL computer automation system. Results: Of the 101 patients included in the study, 69 were male and 32 were female. While the number of patients over 55 years of age was 74, the number of patients under 55 was 27. Left ivolvement was ovserved in 81 of 101 patients and right involvement was seen in 20 patients. Of 101 patients, 55 were diagnosed with rectal cancer and 46 with colon cancer. Of the patients, 59 received cetuximab and 42 received panitumumab. While metastases were identified in the liver in 47 of 101 patients; 54 of the patients had metastases outside the liver. Fifty of 101 patients received first-line treatment, while 51 patients received other-line treatments. There was no statistically significant relationship between age, gender, drug difference, primary tumor localization (diagnosis), site of involvement and disease-free survival (p>0.05); there was a significant correlation between disease-free survival and patients with liver metastases who received other step therapy (p<0.005). Conclusion: İn patients with metastatic colon cancer treated with EGFR inhibitors, a significant correlation was found between patients with liver metastases and those who received non-first-line treatment and disease-free survival. Key words: Metastatic colon canser, EGFR inhibitors, disease-free survival, age, gender, drug, diagnosis, involvement, liver, step therapy.
Açıklama
Anahtar Kelimeler
Onkoloji, Oncology, İç Hastalıkları
